Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absoprtion and a long plasma half-life

被引：0
|
作者：
Knudsen, L. Bjerre [1 ]
Nielsen, P. F. [1 ]
Steensgaard, D. B. [1 ]
Bloch, P. [1 ]
Lau, J. [1 ]
Agersoe, H. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
来源：
DIABETOLOGIA | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
775
引用
收藏
页码：S305 / S306
页数：2
相关论文
共 50 条
  • [41] Once-Daily Human GLP-1 Analog Liraglutide Reduces Systolic BP-A Meta-Analysis of 6 Clinical Trials
    Fonseca, Vivian
    Madsbad, Sten
    Falahati, Ali
    Zychma, Marcin J.
    Plutzky, Jorge
    DIABETES, 2009, 58 : A146 - A146
  • [42] The Relationship between Pharmacokinetics of the Once-Daily Human GLP-1 Analog Liraglutide and Pharmacodynamic Effects on Glycemia, Gastric Emptying and Energy Intake
    Flint, Anne
    Hindsberger, Charlotte
    DIABETES, 2010, 59 : A420 - A420
  • [43] Evaluation of patient reported outcomes in subjects with type 2 diabetes treated with the once-daily human GLP-1 analog liraglutide or glimepiride both as add-on to metformin
    Frid, Anders
    Nauck, Michael A.
    Hermansen, Kjeld
    Kolotkin, Ronette L.
    Hammer, Mette
    Zdrav-Kovic, Milan
    Matthews, David
    DIABETES, 2008, 57 : A574 - A575
  • [44] Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
    Hermansen, K.
    Nauck, M. A.
    Frid, A.
    Shah, N. S.
    Tankova, T.
    Mitha, I. H.
    During, M.
    Zdravkovic, M.
    Matthews, D.
    DIABETOLOGIA, 2008, 51 : S358 - S358
  • [45] Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
    Chatterjee, Dhruba J.
    Khutoryansky, Naum
    Zdravkovic, Milan
    Sprenger, Craig R.
    Litwin, Jeffrey S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (11): : 1353 - 1362
  • [46] The once-daily human GLP-1 analog liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline
    Russell-Jones, David
    Shaw, Jonathan E.
    Brandle, Michael
    Matthews, David
    Frid, Anders
    Zdravkovic, Milan
    Schmitz, Ole
    DIABETES, 2008, 57 : A593 - A594
  • [47] Treatment with Liraglutide, a Once-Daily Human GLP-1 Analog, for 52 Weeks Reduces Weight and Waist Circumference: A Randomized Placebo-Controlled Trial
    Astrup, Arne
    Al Hakim, Mazin
    Savolainen, Markku J.
    Van Gaal, Luc
    Finer, Nick
    Harper, Angela
    Lean, Michael E. J.
    Niskanen, Leo
    Frederik, Mads
    Rissanen, Aila
    Rossner, Stephan
    OBESITY, 2009, 17 : S51 - S51
  • [48] The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
    Anne Flint
    Christoph Kapitza
    Charlotte Hindsberger
    Milan Zdravkovic
    Advances in Therapy, 2011, 28 : 213 - 226
  • [49] The Once-Daily Human Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Improves Postprandial Glucose Levels in Type 2 Diabetes Patients
    Flint, Anne
    Kapitza, Christoph
    Hindsberger, Charlotte
    Zdravkovic, Milan
    ADVANCES IN THERAPY, 2011, 28 (03) : 213 - 226
  • [50] Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
    Vilsboll, T.
    Brock, B.
    Perrild, H.
    Levin, K.
    Lervang, H. -H.
    Kolendorf, K.
    Krarup, T.
    Schmitz, O.
    Zdravkovic, M.
    Le-Thi, T.
    Madsbad, S.
    DIABETIC MEDICINE, 2008, 25 (02) : 152 - 156
12345